10 Best European Stocks For Dividend Investors – Sure Dividend

Revealed on Could sixth, 2026 by Bob Ciura

The U.S. inventory market, as measured by the S&P 500 Index, is probably the most well-known on the earth.

Nevertheless, there are good causes for traders to look outdoors the U.S., significantly these searching for revenue.

However revenue traders ought to turn out to be accustomed to the key European inventory indices:

• FTSE 100: The 100 greatest market cap firms within the U.Ok.
• DAX: 40 of Germany’s greatest blue chip shares
• CAC 40: 40 most vital shares among the many 100 largest market caps on the Euronext Paris

There are various high quality, blue-chip companies with excessive dividends which can be positioned outdoors the USA.

With that in thoughts, now we have created a free record of over 200 excessive dividend shares with dividend yields above 5%.

You possibly can obtain your copy of the excessive dividend shares record beneath:

 

Worldwide dividend shares with increased yields than their U.S.-based friends could also be enticing for revenue traders.

This text will rank the ten highest-yielding European dividend shares within the Positive Evaluation Analysis Database.

Desk of Contents

Excessive Yield European Inventory #10: Novartis AG (NVS)

Novartis researches, develops, and markets merchandise to enhance sufferers’ well being. The corporate affords medicines within the areas of oncology, cardiovascular, dermatology, respiratory, and several other others.

Novartis employs 76,000 individuals and has annual gross sales of about $57 billion. Novartis is integrated in Switzerland, however U.S. traders have entry to the corporate via an American Depositary Receipt, or ADR.

On February 4th, 2026, Novartis raised its annual dividend 18.7% to $4.7402.

On April twenty eighth, 2026, Novartis introduced first quarter outcomes for the interval ending March thirty first, 2026. All figures are in U.S. {dollars}. For the quarter, income fell 0.7% to $13.5, however beat estimates by $44 million.

Adjusted earnings-per-share of $1.99 in contrast unfavorably to $2.28 within the prior yr and was $0.08 lower than anticipated.

Quantity grew 13% and foreign money trade added 4% to outcomes, however these beneficial properties have been offset by a 14% headwind from generic competitors and a 4% decline in pricing.

Income for Entresto, which is used to deal with continual coronary heart failure, fell 42% to $1.31 billion. Cosentyx, which treats plaque psoriasis, grew 2%, or 5% when excluding income deduction changes, to $1.57 billion.

Kisqali, which is used to deal with sure forms of breast most cancers, continues to publish sturdy outcomes as income surged 59% to $1.52 billion.

Novartis repurchased a complete of 10.4 million shares at a median worth of ~$154 in Q1 2026. The corporate initiated a $10 billion share repurchase authorization throughout Q2 2025 that’s scheduled to be accomplished by the top of 2027.

The corporate famous through the This fall 2025 convention name that it must navigate via the most important patent expiration in its historical past in 2026.

We count on Novartis to earn $8.96 per share in 2026, down from $9.06 beforehand.

Click on right here to obtain our most up-to-date Positive Evaluation report on NVS (preview of web page 1 of three proven beneath):

Excessive Yield European Inventory #9: Unilever plc (UL)

Unilever is likely one of the largest client items firms on the earth, producing and advertising and marketing ~400 manufacturers in almost 200 international locations.

Nicely-known manufacturers embrace Ben & Jerry’s, Q-tips, Vaseline, Axe, Dove, Hellmann’s, Knorr and lots of extra. Its merchandise are utilized by greater than 3 billion individuals every single day.

In mid-February, Unilever reported (2/12/26) monetary outcomes for the complete fiscal 2025. It grew its underlying gross sales 3.5% over the prior yr due to 2.0% worth hikes and 1.5% quantity development.

The 30 strongest manufacturers grew their gross sales 4.3% and comprised 78% of whole gross sales. The sturdy manufacturers of the corporate have enabled it to boost costs aggressively and not using a important impact on quantity within the final 4 years.

Nevertheless, as customers have turn out to be extra price-sensitive, worth hikes have moderated in latest quarters.

Unilever offered steerage for gross sales development of 4%-6% in 2026, with no less than 2.0% underlying quantity development and a modest enchancment in working margin (vs. 20.0% in 2025), consistent with its long-term steerage.

Unilever has a major aggressive benefit, particularly the energy of its manufacturers. The corporate generates ~80% of its gross sales from the #1 or #2 place in its markets.

In consequence, Unilever has been capable of increase its dividend for 43 consecutive years in Euros.

Click on right here to obtain our most up-to-date Positive Evaluation report on UL (preview of web page 1 of three proven beneath):

Excessive Yield European Inventory #8: Accenture plc (ACN)

Accenture is an info expertise firm that gives providers resembling consulting, expertise, and outsourcing options.

Its prospects embrace communications and media firms, banks and different monetary firms, the healthcare trade, and public providers, in addition to client items, retail, journey, and different industries.

Accenture reported its most up-to-date quarterly outcomes, for the fiscal second quarter of fiscal 2026, on March nineteenth. The corporate confirmed revenues of $18 billion, up 8% from the earlier yr’s quarter.

Accenture’s gross sales have been up by 4% in fixed currencies, which was just under the currency-neutral income development charge through the earlier quarter.

Accenture recorded new bookings of $22.1 billion, which means that income development will proceed because the book-to-bill ratio was considerably above 1.0.

The brand new bookings development charge was stable as properly, with bookings through the interval being 6% increased in comparison with one yr earlier.

The corporate was capable of earn $2.93 per share through the second quarter, which beat what the analyst neighborhood had estimated by $0.10.

It forecasts natural income development of three% to five% for fiscal 2026, with a steerage midpoint of 4%.

Click on right here to obtain our most up-to-date Positive Evaluation report on ACN (preview of web page 1 of three proven beneath):

Excessive Yield European Inventory #7: Medtronic plc (MDT)

Medtronic is the most important producer of biomedical units and implantable applied sciences on the earth.

It serves physicians, hospitals, and sufferers in additional than 150 international locations and has over 95,000 staff. Medtronic has 4 working segments: Cardiovascular, Medical Surgical, Neuroscience and Diabetes.

The corporate generated $34 billion in income in its final fiscal yr.

In mid-February, Medtronic reported (2/17/26) outcomes for the third quarter of fiscal 2026. Natural income grew 6% over the prior yr’s quarter due to sturdy development in Cardiovascular and Diabetes.

On account of elevated promoting and administrative bills, earnings-per-share dipped -2%, from $1.39 to $1.36, however exceeded the analysts’ consensus by $0.05.

As well as, Medtronic reiterated its steerage for five.5% development of natural income and earnings-per-share of $5.62-$5.66 in fiscal 2026.

Medtronic has raised its dividend for 47 consecutive years. It has grown its dividend by 9.7% per yr on common during the last decade and by 5.6% per yr on common during the last 5 years.

Click on right here to obtain our most up-to-date Positive Evaluation report on MDT (preview of web page 1 of three proven beneath):

Excessive Yield European Inventory #6: Equinor ASA (EQNR)

Equinor ASA is likely one of the largest European publicly traded oil firms.

The corporate is famend for build up Norway’s wealth, with the nation having possession of ~67% of the corporate. The possession curiosity is managed by the Norwegian Ministry of Petroleum and Power.

Whereas it’s primarily a petroleum and gasoline firm working in 36 international locations, Equinor has began diversifying its investments in direction of renewable power. It’s traded each on NYSE and the Oslo inventory trade.

On February fifth, 2026, Equinor raised its base dividend by 5.4% to 1 / 4 charge of $0.39.

On the identical day, Equinor reported its This fall outcomes for the interval ending December thirty first, 2025. Whole income was $25.3
billion, down 8% year-over-year, as decrease realized liquids costs greater than offset increased manufacturing.

Liquids costs fell 14% year-over-year to $58.6/bbl, whereas realized European gasoline costs averaged $10.6/mmbtu.

Whole manufacturing elevated 6% to 2,198 mboe/day, pushed by Johan Castberg, Halten East, and robust U.S. gasoline volumes.

For the quarter, Equinor reported internet revenue of $1.31 billion, down from $2.00 billion in This fall 2024. Web working revenue declined 37% year-over-year to $5.49 billion, impacted by $626 million of internet impairments associated to renewables and worldwide property.

For FY2026, we forecast EPS of $2.58.

Click on right here to obtain our most up-to-date Positive Evaluation report on EQNR (preview of web page 1 of three proven beneath):

Excessive Yield European Inventory #5: Fresenius Medical Care AG (FMS)

Fresenius Medical Care AG is a diversified healthcare company targeted on services and products associated to renal illnesses.

The corporate’s providers embrace kidney dialysis, scientific laboratory testing, and kidney diagnostic procedures. Fresenius Medical is headquartered in Germany.

On February twenty fourth, 2026, Fresenius Medical launched fourth quarter and full yr outcomes. For the quarter, income grew 11.7% to just about $6 billion whereas earnings-per-share totaled $0.85. Each figures have been forward of estimates.

For the yr, income grew 5% at fixed foreign money whereas adjusted EPS of $2.49 in comparison with $1.66 in 2024. Natural income grew 8% for the quarter and full yr.

Quarterly income for Care Supply, previously often known as Well being Care Companies, grew 7% organically. The U.S. enterprise was up 9% as favorable charge and payor combine results, reimbursement laws, and a optimistic influence from diminished implicit worth concessions, partially offset by divestitures.

The worldwide enterprise grew 4% as similar market therapies have been up 1.7%. Worth-Based mostly Care income surged 42% due as soon as once more to increased member months.

As of the top of the quarter, Fresenius Medical had 291,902 sufferers and three,601 clinics worldwide in comparison with 293,620 sufferers and three,628 clinics in Q3 2025.

The corporate expects working revenue to develop by 3% to 7% via 2028. Fresenius Medical is anticipated to earn $2.96 per share in 2026.

Click on right here to obtain our most up-to-date Positive Evaluation report on FMS (preview of web page 1 of three proven beneath):

Excessive Yield European Inventory #4: Novo Nordisk (NVO)

Novo Nordisk A/S ADR is a big world pharmaceutical firm headquartered in Denmark. The corporate focuses on two core enterprise segments: Diabetes & Weight problems Care and Uncommon Illnesses.

The Diabetes & Weight problems Care phase manufactures insulin, associated supply methods, oral anti-diabetic merchandise, and merchandise to deal with weight problems.

The Uncommon Illnesses phase manufactures merchandise for hemophilia and different continual illnesses. Novo Nordisk derives ~92% of income from diabetes and weight problems.

The corporate’s merchandise are marketed in 170 international locations however roughly 48% of internet gross sales are from North America and the remainder is worldwide gross sales.1 Whole income was almost $49.11B in 2025.

Novo Nordisk reported This fall 2025 outcomes on February third, 2026. Firm-wide gross sales have been up 6% in Danish kroner and diluted earnings per share rose 2% to 23.03 DKK ($3.66) from 22.63 DKK ($3.60) on a year-over-year foundation.

Diabetes & Weight problems gross sales elevated 7% to 289,456M DKK ($45,993M) pushed by will increase in Ozempic and Wegovy (weight problems), offset by decrease gross sales for Rybelsus (GLP-1), human insulin, long-acting insulin, fast-acting insulin, Saxenda (weight problems), Victoza (GLP-1), and premix insulin.

The Uncommon Illness phase gross sales rose 5% to 19,608M DKK ($3,116M) brought on by rising uncommon problems medicine, offset by decrease uncommon blood dysfunction medicine.

Click on right here to obtain our most up-to-date Positive Evaluation report on NVO (preview of web page 1 of three proven beneath):

Excessive Yield European Inventory #3: Sanofi (SNY)

Sanofi is a worldwide pharmaceutical chief that develops a wide range of therapeutic therapies and vaccines.

Prescribed drugs account for almost all of gross sales, with vaccines making up the rest. Sanofi produces annual revenues of about $51 billion.

Sanofi is integrated in France, however U.S. traders have entry to the corporate via an American Depositary Receipt, or ADR. Two ADR shares equal one share of the underlying firm.

On January twenty ninth, 2026, Sanofi introduced fourth quarter and full yr outcomes. Until in any other case famous, all figures are listed in U.S. {dollars} and at fixed trade charges.

For the quarter, income grew 23% to $13.5 billion, which topped estimates by $235 million. The corporate’s earnings-per-share per ADR of $0.91 in contrast favorably to $0.68 within the prior yr and was $0.06 greater than anticipated.

For the yr, income grew 4.8% to $50.7 billion whereas earnings-per-share per ADR of $4.53 in comparison with 4.11 in 2024.

Dupixent, which treats sufferers with moderate-to-severe bronchial asthma, had income development of 32.2% through the interval as a result of extra launches and beneficial properties throughout indications and geographies.

Sanofi has 80 merchandise in improvement, with as many as 40 new potential new medicines and vaccines.

Sanofi offered an outlook for 2026 as properly. The corporate expects income to develop at a excessive single-digit share with EPS rising at a barely increased charge.

Click on right here to obtain our most up-to-date Positive Evaluation report on SNY (preview of web page 1 of three proven beneath):

Excessive Dividend Inventory For The Lengthy Run #2: Amcor plc (AMCR)

Amcor plc is likely one of the world’s most distinguished designers and producers of packaging for meals, pharmaceutical, medical, and different client merchandise.

Amcor reported its second quarter outcomes for Fiscal Yr 2026 on February third, 2026. The corporate reported sturdy fiscal Q2 2026 outcomes, with internet gross sales of $5.45 billion, up 68% year-over-year, largely pushed by the Berry International acquisition.

Adjusted profitability improved considerably, with adjusted EBITDA rising 83% to $826 million and adjusted EBIT rising 66% to $603 million, whereas adjusted EPS grew 7% to $0.86.

GAAP internet revenue was $177 million ($0.38 per share) as a result of acquisition-related prices, and free money circulation totaled $289 million after roughly $69 million in integration and restructuring bills.

For the primary half of fiscal 2026, internet gross sales reached $11.19 billion, up 70% year-over-year, reflecting $4.5 billion of acquired gross sales from the Berry mixture.

Amcor reaffirmed its fiscal 2026 steerage, anticipating adjusted EPS of $4.00–$4.15, representing 12–17% fixed foreign money development in contrast with fiscal 2025.

The corporate additionally expects free money circulation of $1.8–$1.9 billion, supported by no less than $260 million in pre-tax synergy advantages from the Berry acquisition.

Click on right here to obtain our most up-to-date Positive Evaluation report on AMCR (preview of web page 1 of three proven beneath):

Excessive Yield European Inventory #1: Perrigo Firm plc (PRGO)

Perrigo is headquartered in Eire and operates within the healthcare sector as a producer of over-the-counter client merchandise.

Its Shopper Self-Care Americas phase is comprised of the U.S., Mexico and Canada client healthcare companies.

The Shopper Self-Care Worldwide phase consists of branded client healthcare enterprise primarily in Europe, but in addition Australia and Israel. The corporate generates ~$4.1 billion in annual income.

On February twenty sixth, 2026, Perrigo introduced fourth quarter and full yr outcomes for the interval ending December thirty first, 2025. For the quarter, income declined 2.5% to $1.11 billion, however this was $17.5 million above estimates.

Adjusted earnings-per-share of $0.77 in comparison with $0.93 within the prior yr and was $0.01 lower than anticipated.

For the yr, income declined 2.8% to $4.25 billion whereas GAAP EPS of -$10.12 was down from -$1.17 within the prior yr as a result of a Goodwill impairment cost. Adjusted earnings-per-share of $2.75 was up from $2.57 in 2024.

Shopper Self-Care Americas had an natural development decline of 6.3%, primarily as a result of weaker ends in toddler system, however decrease demand from OTC contract manufacturing additionally contributed to the lower.

Shopper Self-Care Worldwide’s gross sales have been down 1.0%, as share beneficial properties in key manufacturers, resembling Compeed, and ellaOne, have been offset by weaker OTC class consumption.

The Toddler Formulation phase stays below strategic overview. The corporate introduced a value financial savings program in This fall 2023 referred to as “Challenge Energize” that’s projected to create pre-tax financial savings of $140 million to $170 million by 2026.

Perrigo offered an outlook for 2026 as properly. The corporate now expects natural income development to be down by -1.5% to -5.5% for the yr. Adjusted earnings-per-share is projected to be in a variety of $2.00 to $2.30.

Click on right here to obtain our most up-to-date Positive Evaluation report on PRGO (preview of web page 1 of three proven beneath):

Further Studying

In case you are interested by discovering high-quality dividend development shares and/or different high-yield securities and revenue securities, the next Positive Dividend sources will likely be helpful:

Excessive-Yield Particular person Safety Analysis